Endotoxin enhanced adjuvant effect of liposomes, particularly when antigen and endotoxin are incorporated within the same liposome

Multifunctional Immunoadjuvants for Use in Minimalist Nucleic Acid Vaccines

Subunit vaccines based on antigen-encoding nucleic acids have shown great promise for antigen-specific immunization against cancer and infectious diseases. Vaccines require immunostimulatory adjuvants to activate the innate immune system and trigger specific adaptive immune responses. However, the incorporation of immunoadjuvants into nonviral nucleic acid delivery systems often results in fairly complex structures that are difficult to mass-produce and characterize. In recent years, minimalist approaches have emerged to reduce the number of components used in vaccines. In these approaches, delivery materials, such as lipids and polymers, and/or pDNA/mRNA are designed to simultaneously possess several functionalities of immunostimulatory adjuvants. Such multifunctional immunoadjuvants encode antigens, encapsulate nucleic acids, and control their pharmacokinetic or cellular fate. Herein, we review a diverse class of multifunctional immunoadjuvants in nucleic acid subunit vaccines and provide a detailed description of their mechanisms of adjuvanticity and induction of specific immune responses.

In vivo distribution of particulate antigens and liposomes in murine spleen. A possible role in the humoral immune response

Several particulate antigens and liposomes were intravenously injected in mice in order to study their localization patterns in spleen and liver. Liposomes have been proposed as promising carriers for haptens and antigens. It was studied whether the phospholipid composition, cholesterol content and charge of the liposomes played a role in their distribution within the spleen. Different thymus-independent type 1 and type 2 and thymus-dependent particulate antigens as well as liposomes were labeled with the lipophilic fluorochrome Di-I. After labeling they were intravenously injected and spleens and livers were removed at different time intervals and prepared for light- and fluorescence-microscopy. We have observed that all particulate antigens and liposomes administered to the mice localized according to the same distribution pattern in the spleen. After 2 and 4 h particles were located in macrophages of the marginal zone and after 24 h white pulp macrophages had also ingested particulate antigens and liposomes. So we conclude that the distribution of the particulate antigens and liposomes in the spleen is independent of the immunological nature of the particles. Results are discussed with respect to the question whether or not the distribution of particulate antigens and liposome associated antigens or haptens, may be a crucial factor in determining the type of immune response to be elicited.

Lipopolysaccharide, lipid A, and liposomes containing lipid A as immunologic adjuvants

Numerous studies have demonstrated that most or all of the potent adjuvant activity of Gram-negative bacterial endotoxin resides in the lipid A moiety of lipopolysaccharide (LPS). Synthetic analogues of lipid A have provided insights into structure-activity relationships. Several cellular mechanisms of LPS and lipid A adjuvant activities have been identified. Activation of macrophages by LPS or lipid A results in cytokine secretions that enhance the immune response. LPS and lipid A cause recruitment of antigen-presenting cells, particularly macrophages. Liposomes containing lipid A serve as an in vivo adjuvant to recruit increased numbers of macrophages. Liposomal lipid A that has been phagocytized by cultured macrophages also serves as an "intracellular adjuvant" to cause increased immunologic presentation of liposomal antigen by the macrophages to specific T lymphocytes. Lipid A can abolish suppressor T cell activity, resulting in increased immune responses to polysaccharide antigens. Upon combination of lipid A or lipid A analogues with nonionic block polymers, modulation of murine antibody isotypes can be achieved with antibodies against a variety of antigens in vivo. Liposomes containing monophosphoryl lipid A (MPL) have been utilized in a phase I clinical trial of a proposed malaria vaccine in humans. The liposomal malaria vaccine resulted in very high levels of antibodies against the malarial antigen, and despite the presence of huge amounts of MPL (up to 2.2 mg), the liposomal lipid A was nonpyrogenic and safe for use in humans. Lipid A and lipid A analogues, and liposomes or other carriers containing lipid A, have shown considerable promise both as adjuvants for immunization of animals and for human vaccines.

Adjuvants--a balance between toxicity and adjuvanticity

Adjuvants have been used to augment the immune response in experimental immunology as well as in practical vaccination for more than 60 years. The chemical nature of adjuvants, their mode of action and the profile of their side effects are highly variable. Some of the side effects can be ascribed to an unintentional stimulation of different mechanisms of the immune system whereas others may reflect general adverse pharmacological reactions. The most common adjuvants for human use today are still aluminium hydroxide, aluminium phosphate and calcium phosphate although oil emulsions, products from bacteria and their synthetic derivatives as well as liposomes have also been tested or used in humans. In recent years monophosphoryl lipid A, ISCOMs with Quil-A and Syntex adjuvant formulation (SAF) containing the threonyl derivative of muramyl dipeptide have been under consideration for use as adjuvants in humans. At present the choice of adjuvants for human vaccination reflects a compromise between a requirement for adjuvanticity and an acceptable low level of side effects.

Liposomes as carriers of antigens and adjuvants

Liposomes have been widely used as carriers of protein or peptide antigens. Antigenic materials can be attached to the outer surface, encapsulated within the internal aqueous spaces, or reconstituted within the lipid bilayers of the liposomes. The natural tendency of liposomes to interact with macrophages has served as the primary rationale for utilizing liposomes as carriers of antigens. Liposomes also serve as carriers of a variety of adjuvants and mediators, including lipid A, muramyl dipeptide and its derivatives, interleukin-1, and interleukin-2. Research utilizing in vitro cell culture models has demonstrated that liposomes containing both appropriate antigens and major histocompatibility gene complex molecules can induce antigen-specific genetically restricted cytotoxic T lymphocytes. Liposomes induce immune reactions through classical interactions with antigen presenting cells. However, modelling experiments have also demonstrated that liposomes can even substitute for antigen presenting cells, and cell-free genetically restricted and nonrestricted presentation of antigens by liposomes to helper T lymphocytes has been demonstrated. Liposomes are successful for inducing potent immunity in vivo and they are now being employed in numerous immunization procedures and as vehicles for candidate vaccines.

Immunological studies with liposome-bound corynetoxins

Attempts were made to raise antibodies against corynetoxins, a family of toxins responsible for annual ryegrass toxicity. The glycolipid nature of corynetoxins made them ideally suited for incorporation into the structure of small unilamellar liposomes. Sheep were injected with corynetoxin liposomes with and without adjuvants such as lipid A and muramyl dipeptide, and the sera tested for anti-corynetoxin antibody. Similarly, rabbits were injected with hydrolysed corynetoxin coupled to human IgG and keyhole limpet haemocyanin and with corynetoxin coupled to bovine serum albumin. These preparations were administered with complete Freund's adjuvant. The failure of any of these preparations to elicit an anti-corynetoxin antibody response in either sheep or rabbits is discussed.

Liposomes, lipid A, and aluminum hydroxide enhance the immune response to a synthetic malaria sporozoite antigen

A liposome-encapsulated cloned protein (R32tet32) containing sequences from the tetrapeptide repeat region of the circumsporozoite protein of Plasmodium falciparum sporozoites was examined for immunogenicity with rabbits and monkeys. Effects of adjuvants were tested by encapsulation of the antigen in liposomes either lacking or containing lipid A and adsorption with aluminum hydroxide (ALUM). When rabbits were immunized with R32tet32 alone, a primary antibody response was not seen and a secondary response did not appear until 32 to 36 weeks after boosting. Immunization with ALUM-adsorbed R32tet32 resulted in a minimal primary antibody response. A moderate secondary antibody response was detected within 2 weeks after boosting, but antibody levels decreased to preimmunization levels 8 weeks after boosting. When R32tet32 was encapsulated in liposomes containing lipid A, strong primary and secondary antibody responses were observed. Strong primary and secondary responses also were obtained when R32tet32 was encapsulated in liposomes either containing or lacking lipid A and the liposomes were adsorbed with ALUM. The strongest antibody response was obtained by immunization with ALUM-adsorbed liposomes containing lipid A and R32tet32, suggesting that the adjuvant effects of liposomes, lipid A, and ALUM were additive or synergistic.

Immunogenic properties of Staphylococcus aureus and Streptococcus agalactiae administered separately and in combination to lactating cows

Composite bacterins of Staphylococcus aureus and Streptococcus agalactiae, or either bacterin alone, were administered systemically to groups of lactating cows. The response to each bacterin was unaffected by the simultaneous administration of the antigens when assessed by comparing the antibody levels in milk by enzyme-linked immunosorbent assay. There was no evidence of cross reactivity of the antigens studied, nor immunopotentiation by either bacteria.

Localization of intravenously injected lipopolysaccharide (LPS) in the spleen of the mouse. An immunoperoxidase and histochemical study

In earlier studies we investigated the in vivo effects of lipopolysaccharide (LPS) on lymphoid and non-lymphoid cells in the mouse spleen. In order to find out whether LPS localizes in and/or on cells that are affected by this compound, the aim of the present study was to investigate the localization of intravenously injected LPS in the mouse spleen using an immunoperoxidase technique. At different time points after injection, the localization of LPS is demonstrated and LPS-containing cells are characterized. Most of the injected LPS has been taken up by marginal zone macrophages at 2 h after its administration whereas macrophages in the red pulp and at the periphery of the white pulp (marginal metallophils) have ingested less LPS. In the periarteriolar lymphocyte sheath, LPS is concentrated in a large number of acid phosphatase-negative, Ia-positive, large branched cells which were suggested to represent interdigitating cells. Moreover an extracellular dendritic localization pattern of LPS is demonstrated in the corona and central parts of the follicles at different time intervals after its injection. The significance of the localization pattern of LPS in the mouse spleen is discussed.

The effect of surface sugars on liposomes in immunopotentiation

The effect of surface sugars of liposomes on the immunological responses to entrapped antigen has been investigated. alpha-Mannose and beta-galactose were grafted on the surface of liposomes containing lysozyme by covalent coupling of p-aminophenyl-D-glycosides to phosphatidyl ethanolamine liposomes using glutaraldehyde. Subcutaneous administration of antigen entrapped in beta-galactose liposomes stimulated an antibody response comparable to that elicited by sugar-free neutral liposomes. However, alpha-mannose bearing liposomes with entrapped lysozyme elicited an immune response similar to that induced by lysozyme in saline. Based on these observations it is suggested that alpha-mannose liposomes, that are specifically recognized by macrophages, are taken up rapidly by receptor mediated endocytosis and that the entrapped antigen is then rapidly degraded, resulting in low antibody production.

Immunoglobulins as targeting agents for liposome encapsulated drugs

Recent literature dealing with the immunoglobulin-liposome combination as a tool for drug targeting is reviewed. Mechanisms for binding of immunoglobulins to liposomes are discussed. Results obtained so far by using this concept both to induce specific liposome-cell interactions in in vitro cell cultures and to target drug containing liposomes to selected tissues in animal studies are evaluated.